Cargando…
Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis
Empagliflozin (EMPA) is a novel sodium-glucose cotransporter 2 inhibitor (SGLT2i) that produces protective cardiovascular-renal outcomes in patients with diabetes. However, the effects of EMPA on obesity-related kidney disease have not been determined. The heme oxygenase-1 (HO-1)–adiponectin axis is...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248377/ https://www.ncbi.nlm.nih.gov/pubmed/35784553 http://dx.doi.org/10.3389/fendo.2022.907984 |
_version_ | 1784739354156990464 |
---|---|
author | Ye, Tongtong Zhang, Jingwen Wu, Di Shi, Junfeng Kuang, Zengguang Ma, Yuting Xu, Qian Chen, Bing Kan, Chengxia Sun, Xiaodong Han, Fang |
author_facet | Ye, Tongtong Zhang, Jingwen Wu, Di Shi, Junfeng Kuang, Zengguang Ma, Yuting Xu, Qian Chen, Bing Kan, Chengxia Sun, Xiaodong Han, Fang |
author_sort | Ye, Tongtong |
collection | PubMed |
description | Empagliflozin (EMPA) is a novel sodium-glucose cotransporter 2 inhibitor (SGLT2i) that produces protective cardiovascular-renal outcomes in patients with diabetes. However, the effects of EMPA on obesity-related kidney disease have not been determined. The heme oxygenase-1 (HO-1)–adiponectin axis is an essential antioxidant system with anti-apoptotic and anti-inflammatory properties. This study explored whether EMPA improves obesity-related kidney disease through regulation of the renal HO-1-mediated adiponectin axis. C57BL/6J mice were assigned to control, high-fat diet (HFD) groups, and EMPA (10 mg/kg) groups. HFD mice showed metabolic abnormality and renal injury, including increased urinary albumin excretion, morphologic changes, and lipid accumulation. EMPA treatment improved metabolic disorders and attenuated lipotoxicity-induced renal injury. Furthermore, EMPA treatment ameliorated renal NLRP3 inflammasome activity and upregulated the HO-1–adiponectin axis. Our findings indicate that EMPA improves obesity-related kidney disease through reduction of NLRP3 inflammasome activity and upregulation of the HO-1–adiponectin axis, suggesting a novel mechanism for SGLT2i-mediated renal protection in obesity. |
format | Online Article Text |
id | pubmed-9248377 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92483772022-07-02 Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis Ye, Tongtong Zhang, Jingwen Wu, Di Shi, Junfeng Kuang, Zengguang Ma, Yuting Xu, Qian Chen, Bing Kan, Chengxia Sun, Xiaodong Han, Fang Front Endocrinol (Lausanne) Endocrinology Empagliflozin (EMPA) is a novel sodium-glucose cotransporter 2 inhibitor (SGLT2i) that produces protective cardiovascular-renal outcomes in patients with diabetes. However, the effects of EMPA on obesity-related kidney disease have not been determined. The heme oxygenase-1 (HO-1)–adiponectin axis is an essential antioxidant system with anti-apoptotic and anti-inflammatory properties. This study explored whether EMPA improves obesity-related kidney disease through regulation of the renal HO-1-mediated adiponectin axis. C57BL/6J mice were assigned to control, high-fat diet (HFD) groups, and EMPA (10 mg/kg) groups. HFD mice showed metabolic abnormality and renal injury, including increased urinary albumin excretion, morphologic changes, and lipid accumulation. EMPA treatment improved metabolic disorders and attenuated lipotoxicity-induced renal injury. Furthermore, EMPA treatment ameliorated renal NLRP3 inflammasome activity and upregulated the HO-1–adiponectin axis. Our findings indicate that EMPA improves obesity-related kidney disease through reduction of NLRP3 inflammasome activity and upregulation of the HO-1–adiponectin axis, suggesting a novel mechanism for SGLT2i-mediated renal protection in obesity. Frontiers Media S.A. 2022-06-17 /pmc/articles/PMC9248377/ /pubmed/35784553 http://dx.doi.org/10.3389/fendo.2022.907984 Text en Copyright © 2022 Ye, Zhang, Wu, Shi, Kuang, Ma, Xu, Chen, Kan, Sun and Han https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Ye, Tongtong Zhang, Jingwen Wu, Di Shi, Junfeng Kuang, Zengguang Ma, Yuting Xu, Qian Chen, Bing Kan, Chengxia Sun, Xiaodong Han, Fang Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis |
title | Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis |
title_full | Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis |
title_fullStr | Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis |
title_full_unstemmed | Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis |
title_short | Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis |
title_sort | empagliflozin attenuates obesity-related kidney dysfunction and nlrp3 inflammasome activity through the ho-1–adiponectin axis |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248377/ https://www.ncbi.nlm.nih.gov/pubmed/35784553 http://dx.doi.org/10.3389/fendo.2022.907984 |
work_keys_str_mv | AT yetongtong empagliflozinattenuatesobesityrelatedkidneydysfunctionandnlrp3inflammasomeactivitythroughtheho1adiponectinaxis AT zhangjingwen empagliflozinattenuatesobesityrelatedkidneydysfunctionandnlrp3inflammasomeactivitythroughtheho1adiponectinaxis AT wudi empagliflozinattenuatesobesityrelatedkidneydysfunctionandnlrp3inflammasomeactivitythroughtheho1adiponectinaxis AT shijunfeng empagliflozinattenuatesobesityrelatedkidneydysfunctionandnlrp3inflammasomeactivitythroughtheho1adiponectinaxis AT kuangzengguang empagliflozinattenuatesobesityrelatedkidneydysfunctionandnlrp3inflammasomeactivitythroughtheho1adiponectinaxis AT mayuting empagliflozinattenuatesobesityrelatedkidneydysfunctionandnlrp3inflammasomeactivitythroughtheho1adiponectinaxis AT xuqian empagliflozinattenuatesobesityrelatedkidneydysfunctionandnlrp3inflammasomeactivitythroughtheho1adiponectinaxis AT chenbing empagliflozinattenuatesobesityrelatedkidneydysfunctionandnlrp3inflammasomeactivitythroughtheho1adiponectinaxis AT kanchengxia empagliflozinattenuatesobesityrelatedkidneydysfunctionandnlrp3inflammasomeactivitythroughtheho1adiponectinaxis AT sunxiaodong empagliflozinattenuatesobesityrelatedkidneydysfunctionandnlrp3inflammasomeactivitythroughtheho1adiponectinaxis AT hanfang empagliflozinattenuatesobesityrelatedkidneydysfunctionandnlrp3inflammasomeactivitythroughtheho1adiponectinaxis |